Covalent Targeting Leads to the Development of a LIMK1 Isoform-Selective Inhibitor.

Mandel S, Hanke T, Prendiville N, Baena-Nuevo M, Berger LM, Farges F, Schwalm MP, Berger BT, Kraemer A, Elson L, Saraswati H, Abdul Azeez KR, Dederer V, Mathea S, Corrionero A, Alfonso P, Keller S, Gstaiger M, Krause DS, Müller S, Röhm S, Knapp S